Tatva Chintan Pharma Chem Ltd (TATVA) is currently trading at 1,572.10 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Tatva Chintan Pharma Chem Limited is an integrated specialty chemicals manufacturer producing Phase Transfer Catalysts (PTC), Structure Directing Agents (SDA), Electrolyte Salts & Solutions (ESS) and Pharma & Agrochemical Intermediates (PASC), with two Gujarat manufacturing sites, DSIR‑recognised R&D and international subsidiaries supporting exports to 30+ countries. Q2 FY27 was a record quarter: consolidated revenue rose 76% YoY to ₹2,173 million, EBITDA was ₹407 million with a 19% margin and PAT improved materially to ₹215 million (9.9% margin), reflecting strong top-line traction and improving profitability for Tatva Chintan despite temporary input cost headwinds. The company is differentiated by green chemistries (electrolysis and continuous flow chemistry), a deep SDA franchise benefitting from EURO 7 driven demand, and leadership positions such as being the second largest global SDA manufacturer and largest Indian producer of electrolyte salts, giving Tatva Chintan meaningful technical moats. Financial discipline and deleveraging are visible: H1FY27 RoE improved and Debt/EBITDA (annualised) reduced to 1.16x, while management emphasised normalisation of solvent shortages and freight pressures in Q3, indicating expectation of margin recovery and operational leverage conversion as capacity expansion comes online.

Over the past 52 weeks, Tatva Chintan Pharma Chem Ltd has traded between a low of ₹1,045.70 and a high of ₹2,109.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Tatva Chintan Pharma Chem Ltd has a market capitalization of approximately 3,677.46. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Tatva Chintan Pharma Chem Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 58.45 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 3,677.46 Cr, Tatva Chintan Pharma Chem Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Tatva Chintan Pharma Chem Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Tatva Chintan Pharma Chem Ltd is 58.45. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The last earnings date listed for Q1 FY26-27 is 17 July 2026, when the company’s board approved the unaudited financial statements.

Revenue from operations for Q4 FY26 was INR 134.1 crore (INR 1,341 million), up 24% year-on-year and 2% quarter-on-quarter.

It is a directive issued by the Indian government under the Essential Commodities Act to manage and prioritize the distribution of natural gas due to disruptions in international LNG supply.